Clinical trial · Interventional
Ketamine as Adjunctive Analgesic With Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery
NCT02462681CI-TRIAL-00028395completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to investigate the safety and the analgesic efficacy of adding Ketamine to bupivacaine 0.25% in thoracic PVB in patients undergoing modified radical mastectomy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Pain | — | UNRESOLVED | — |
| Chronic Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| paravertebral block | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- bupivacaine group in paravertebral block
- description
- patients will be received 20 ml of bupivacaine 0.25% paravertebrally, divided into 3-4 ml in each level
- interventionNames
- Drug: paravertebral block
- type
- ACTIVE_COMPARATOR
- label
- bupivacaine + 0.5 mg/kg ketamine group in paravertebral block
- description
- patients will be received 20 ml of bupivacaine 0.25% + 0.5 mg/kg ketamine paravertebrally divide into 3-4 ml in each level
- interventionNames
- Drug: paravertebral block
- type
- ACTIVE_COMPARATOR
- label
- bupivacaine + 1 mg/kg ketamine group in paravertebral block
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 25 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * all patients scheduled for elective modified radical mastectomy with axillary dissection will be enrolled in the study Exclusion Criteria: * patients with a known allergy to the study drugs * patients with bleeding diathesis * patients with infection at the site of injection * patients with central neuropathy * patients with liver impairment * patients with renal impairment * drugs or alcohol abusers * patients with psychiatric illnesses
References
Publications (0)
Data not yet available
No reference posted for this study.